IARC Monographs on the Evaluation of Carcinogenic Risks to Humans IARC Monograph Evaluations

Similar documents
The carcinogenicity of benzene. The IARC Monograph Vol 120. Kurt Straif, MD MPH PhD. PSA, Stavanger, 25 October 2018

IARC Monographs, Vol 98, 2007 Occupational Exposure as a Firefighter. Kurt Straif, MD MPH PhD

Contemporary Issues in Risk Assessment. June 17, 2015

IARCs klassificering av dieselavgaser 2012

Interpretation of Epidemiologic Studies

Discussion of Changes in the Draft Preamble

pharmaceuticals volume 100 A A review of human carcinogens iarc monographs on the evaluation of carcinogenic risks to humans

The IARC Monographs, Vol 100: A review and update on occupational carcinogens

Identification et évaluation des cancérogènes : Les Monographies du CIRC

Recent Results from the IARC Monographs: Carcinogenicity of Consuming Red & Processed Meat, Coffee and Very Hot Beverages

Classifying Foods as Carcinogenic? A Case Study of Red and Processed Meats.

Comments DRAFT Preamble to the IARC Monograph. Health and Safety Department International Union, UAW 8000 East Jefferson Avenue Detroit, MI 48214

Breast Cancer and Shift Work The IARC Evaluation. Roel Vermeulen, PhD IRAS, Environmental Epidemiology Division Utrecht University, the Netherlands

WORLD HEALTH ORGANIZATION INTERNATIONAL AGENCY FOR RESEARCH ON CANCER. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans PREAMBLE

The Carcinogenicity of Glyphosate Kate Z. Guyton, PhD DABT

Priorities for Occupational Cancer Research and Prevention in Canada Paul A. Demers, PhD

A review of human carcinogens -Part F: Chemical agents and related occupations

Scientific Facts on. Mercury

Shift Work: An overview of health effects and potential interventions

Visiting scientists Dr Robert Baan Dr Aaron Cohen (until June 2012) Dr Christopher Portier

Recent developments and evaluations from the IARC Monographs pertinent to the estimation of the global burden of occupational cancer.

IARC Research Actions on Radiofrequencies

Carcinogenicity of Glyphosate The IARC Monographs. Dana Loomis PhD Deputy Head Monographs Programme

Part 2. Chemical and physical aspects

Arbeitsbedingte Krebserkrankungen Einstufung und Bewertung

Table of contents. 1 Dr David Thomas Fred Hutchinson Cancer Research Center (retired) 5 Dr Paul Pinsky United States National Cancer Institute

Evaluation of Ramazzini Institute Aspartame Studies and EFSA s Assessment

Cancer Key facts The problem Cancer causes

Polychlorinated Biphenyls (PCBs)

DRAFT Preamble to the IARC Monographs

The number of new cases is expected to rise by about 70% over the next 2 decades.

Narrative overviews. Lesley Rushton Epidemiology and Public Health

4/2/2012. IARC Monograph Evaluations. Scrotal Cancer among Chimney Sweeps. What do we Know about Occupational Carcinogens?

> Low-frequency magnetic fields and cancer

Health Risks Assessment A WHO perspective. Dr E. van Deventer

Processed meats and cancer Mariana C. Stern, PhD Associate Professor of Preventive Medicine & Urology USC Norris Comprehensive Cancer Center

The Burden of Work-related Cancer in Great Britain

2B: possibly carcinogenic to humans! A communication challenge

Avoidable Occupational and Environmental Causes of Cancer

RF and Health: A WHO Perspective

Approaches used to evaluate mechanistic data for the Report on Carcinogens (RoC) by the National Toxicology Program (NTP)

Executive Summary. This report provides the findings of a ten-month study requested by the Maryland

Air pollution as a major risk factor for cancer

Conclusions of the BioInitiative Report. Michael Kundi Medical University of Vienna BioInitiative Organizing Committee

CONTENTS NOTE TO THE READER...1 LIST OF PARTICIPANTS...3

Addendum to the 12th Report on Carcinogens

biological agents volume 100 B A review of human carcinogens iarc monographs on the evaluation of carcinogenic risks to humans

CONTENTS NOTE TO THE READER... 1

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans

Instructions to Authors

2012 NAPA Strategic Plan. 4 Focus Areas

PH 150 MIDTERM KEY VERSION A October 29, 2003

Annie J. Sasco, MD, MPH, MS, DrPH

RF and Health: A WHO Perspective

Hormonally active contaminants- Interactions and effects on food safety. Helen Håkansson

False Positives & False Negatives in Cancer Epidemiology

Figure 1. Comparison of Cancer Incidence Rates 1 of Individual Census Tracts with Louisiana, All Cancers Combined,

The IARC Monographs Programme

IARC Monographs- Classifications Page 1 sur 1 AGENTS CLASSIFIED BY THE IARC MONOGRAPHS, VOLUMES 1-113

CLCW Carcinogens What You Need to Know. CLCW SME training August, 2017

Media centre. Dioxins and their effects on human health. Key Facts. 1 of 7 1/7/11 1:31 PM

5. Summary of Data Reported and Evaluation 5.1 Exposure data

DRAFT COMMISSION DELEGATED REGULATION (EU) /... of XXX

Environmental Exposures and Cancer Hazards

Night Shift Work and Occupational Exposures

Introduction. What is Shiftwork. Normal Human Rhythm. What are the Health Effects of Shiftwork? Blue Light

12 HEALTH RISK ASSESSMENT

Recent developments for combining evidence within evidence streams: bias-adjusted meta-analysis

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. VOLUME 93 Carbon Black, Titanium Dioxide, and Talc

Challenges of MoA/HRF under CLH

EVALUATION DE LA CANCEROGENESE DES MEDICAMENTS QUOI DE NEUF?

Risk Assessment Issues: Asbestos p. 100 Review of Epidemiological Evidence for Health Effects in Workers Exposed to MMMFs p. 103

A review of the impact of shift work on occupational cancer

Radiofrequency Radiation

The IARC Monographs Programme The Identification of Occupational Carcinogens. Kurt Straif, MD PhD MPH. Toronto, 24 February 2014

5. Summary of Data Reported and Evaluation

DOSE SELECTION FOR CARCINOGENICITY STUDIES OF PHARMACEUTICALS *)

Epidemiology of weak associations The case of nutrition and cancer. Paolo Boffetta Icahn School of Medicine at Mount Sinai New York NY

Dithianon DITHIANON (180)

Alliance of Nuclear Worker Advocacy Groups

Risk Communication Towards a sustainable working life Forum on new and emerging OSH risks Brussels, October

Symposium 2000: Low frequency EMF, Visible Light, Melatonin and Cancer

R. Balansky 1,2, F. D Agostini 2, A. Izzotti 2, P. Kalpakam 3, V.E. Steele 4, S. De Flora 2

Policy Implications. Virginia M. Weaver, MD, MPH Associate Professor, Environmental Health Sciences and Medicine Johns Hopkins University

VICH GL23: Studies to evaluate the safety of residues of veterinary drugs in human food: genotoxicity testing

IOM Research Project: P937/100 December 2011

Nickel : one of the strongest documented metal

Cancer prevention and control in the context of an integrated approach

ACTIVITIES DEVELOPED AND PROMOTED BY WHO

History of tonsillar cancer icd 10 code

the heart of health and safety

Questions and Answers about Prostate Cancer Screening with the Prostate-Specific Antigen Test

Anne-Marie Nicol, PhD Assistant Professor School of Population and Public Health

Cancer among Nordic firefighters - study results and future plans

Infant TDS. Results of the ANSES study on dietary exposure of children under 3 years of age to chemical substances

Environmental Exposures and Immune Function

Comments from recent meeting chairs and subgroup chairs on the 1991 version of the Preamble

Mr. Bruce Allen. Dr. Harvey Clewell.

Alcohol and cancer. Peter Anderson MD, MPH, PhD

David O. Carpenter, MD. Institute for Health and the Environment University at Albany Rensselaer, NY

Transcription:

IARC Monographs on the Evaluation of Carcinogenic Risks to Humans IARC Monograph Evaluations

Subgroup work humans Sufficient evidence Limited evidence Inadequate evidence Evidence suggesting lack of carcinogenicity experimental animals Sufficient evidence Limited evidence Inadequate evidence Evidence suggesting lack of carcinogenicity Mechanistic and other relevant data Mechanistic data weak, moderate, or strong? Mechanism likely to be operative in humans? Overall evaluation Group 1 Group 2A Group 2B Group 3 Group 4 Carcinogenic to humans Probably carcinogenic to humans Possibly carcinogenic to humans Not classifiable as to its carcinogenicity to humans Probably not carcinogenic to humans

Evaluating human data (Subgroup 2) humans experimental animals Mechanistic and other relevant data Preamble Part B, Section 6(a) Sufficient evidence Limited evidence Inadequate evidence Causal relationship has been established Chance, bias, and confounding could be ruled out with reasonable confidence Causal interpretation is credible Chance, bias, or confounding could not be ruled out Studies permit no conclusion about a causal association Several adequate studies covering the full range of Evidence suggesting exposure levels are mutually consistent in not showing a lack of carcinogenicity positive association at any observed level of exposure Conclusion is limited to cancer sites and conditions studied

Sufficient evidence Identifying human tumour sites There is sufficient evidence in humans for the carcinogenicity of tobacco smoking. Tobacco smoking causes cancer of the lung, oral cavity, naso-, oro- and hypopharynx,... Sufficient evidence and ESLC There is sufficient evidence in humans for the carcinogenicity of tamoxifen. Tamoxifen causes cancer of the endometrium. An inverse relationship has been established between exposure to tamoxifen and cancer of the female breast. Limited evidence There is limited evidence in humans for the carcinogenicity of Ethylene Oxide. A positive association has been observed between exposure to Ethylene Oxide and cancers of the breast and lymphatic and haematopoietic malignancies.

Evaluating experimental animal data (Subgroup 3) humans experimental animals Preamble Part B, Section 6(b) Mechanistic and other relevant data Sufficient evidence Limited evidence Inadequate evidence Causal relationship has been established through either: - Multiple positive results (2 species, studies, sexes of GLP) - Single unusual result (incidence, site/type, age, multi-site) Data suggest a carcinogenic effect but: (e.g.) single study, benign tumours only, promoting activity only Studies permit no conclusion about a carcinogenic effect Evidence suggesting lack of carcinogenicity Adequate studies in at least two species show that the agent is not carcinogenic Conclusion is limited to the species, tumour sites, age at exposure, and conditions and levels of exposure studied

Identifying animal tumour sites The Working Group considers that a causal relationship has been established between the agent and an increased incidence of malignant neoplasms or of an appropriate combination of benign and malignant neoplasms originating from the same organ in (a) two or more species of animals or (b) two or more independent studies in one species carried out at different times or in different laboratories or under different protocols. An increased incidence of tumours originating from the same organ in both sexes of a single species in a well-conducted study, ideally conducted under Good Laboratory Practices, can also provide sufficient evidence. A single study in one species and sex might be considered to provide sufficient evidence of carcinogenicity to identify tumour sites when malignant neoplasms occur to an unusual degree with regard to incidence, site, type of tumour or age at onset, orwhenthereare strong findings of tumours at multiple sites. Applying these criteria for the evaluation of carcinogenicity to a species and target site-specific level, the WG identifies sites established as causally related.

Evaluating mechanistic and other data (Subgroup 4) humans experimental animals Mechanistic and other relevant data Preamble Part B, Section 6(c) Are the mechanistic data weak, moderate, or strong? Have the mechanistic events been established? Are there consistent results in different experimental systems? Is the overall database coherent? Has each mechanism been challenged experimentally? Do studies demonstrate that suppression of key mechanistic processes leads to suppression of tumour development? Is the mechanism likely to be operative in humans? Are there alternative explanations? Could different mechanisms operate in different dose ranges, in humans and experimental animals, or in a susceptible group? Note: an uneven level of support for different mechanisms may reflect only the resources focused on each one

Plenary session humans Sufficient evidence Limited evidence Inadequate evidence Evidence suggesting lack of carcinogenicity experimental animals Sufficient evidence Limited evidence Inadequate evidence Evidence suggesting lack of carcinogenicity Mechanistic and other relevant data Mechanistic data weak, moderate, or strong? Mechanism likely to be operative in humans? Overall evaluation Group 1 Group 2A Group 2B Group 3 Group 4 Carcinogenic to humans Probably carcinogenic to humans Possibly carcinogenic to humans Not classifiable as to its carcinogenicity to humans Probably not carcinogenic to humans

The plenary sessions will combine the human and experimental evaluations EVIDENCE IN EXPERIMENTAL ANIMALS Sufficient Limited Inadequate ESLC Sufficient Limited EVIDENCE IN HUMANS Inadequate Group 2A (probably carcinogenic) Group 2B (possibly carcinogenic) Group 1 (carcinogenic to humans) Group 2B (possibly carcinogenic) (exceptionally, Group 2A) Group 3 (not classifiable) ESLC Group 4

Mechanistic data can be pivotal when the human data are not conclusive EVIDENCE IN EXPERIMENTAL ANIMALS Sufficient Limited Inadequate ESLC Sufficient Group 1 Limited 1 strong evidence in exposed humans Group 2A 2A belongs to a mechanistic class where other members are classified in Groups 1 or 2A Group 2B (exceptionally, Group 2A) EVIDENCE IN HUMANS Inadequate ESLC 1 strong evidence in exposed humans 2A strong evidence mechanism also operates in humans Group 2B 3 strong evidence mechanism does not operate in humans 2A belongs to a mechanistic class 2B with supporting evidence from mechanistic and other relevant data Group 3 Group 3 2A belongs to a mechanistic class 2B with strong evidence from mechanistic and other relevant data Group 3 Group 3 4 consistently and strongly supported by a broad range of mechanistic and other relevant data Group 4

Diesel engine exhaust (V 105) The Working Group concluded that there was sufficient evidence in humans for the carcinogenicity of diesel-engine exhaust. sufficient evidence in experimental animals for the carcinogenicity of whole diesel-engine exhaust, of dieselengine exhaust particles and of extracts of diesel-engine exhaust particles. strong evidence for the ability of whole diesel-engine exhaust to induce cancer in humans through genotoxicity. Overall evaluation Diesel engine exhaust is carcinogenic to humans (Group 1)

Polychlorinated biphenyls (V 107) The Working Group concluded that there was sufficient evidence in humans for the carcinogenicity of polychlorinated biphenyls. sufficient evidence in experimental animals for the carcinogenicity of PCB126, PCB118, Aroclor 1260, Aroclor 1254, and Kanechlor 500. Strong evidence of an AhR-mediated mechanism of carcinogenesis identical to that of 2,3,7,8-TCDD. Overall evaluation Polychlorinated biphenyls are carcinogenic to humans (Group 1) Dioxin-like polychlorinated biphenyls are carcinogenic to humans (Group 1).

Shift-work, Overall Evaluation Vol. 98 6.1 humans There is limited evidence in humans for the carcinogenicity of shiftwork that involves night work. 6.2 experimental animals There is sufficient evidence in experimental animals for the carcinogenicity of light during the daily dark period (biological night). 6.3 Overall evaluation Shiftwork that involves circadian disruption is probably carcinogenic to humans (Group 2A)

Arsenic, Vol 84, Section 3 There is limited evidence in experimental animals for the carcinogenicity of sodium arsenite, calcium arsenate and arsenic trioxide. There is inadequate evidence in experimental animals for the carcinogenicity of sodium arsenate and arsenic trisulfide. Taken together, the studies on inorganic arsenic provide limited evidence for carcinogenicity in experimental animals.

Lead, Vol. 97, Section 3 There is sufficient evidence in experimental animals for the carcinogenicity of lead acetate, lead subacetate, lead chromate, and lead phosphate. There is inadequate evidence in experimental animals for the carcinogenicity of lead oxide and lead arsenate. There is sufficient evidence in experimental animals for the carcinogenicity of inorganic lead compounds.

The categorization of an agent is a matter of scientific judgement... It is recognized that the criteria for these evaluations cannot encompass all of the factors that may be relevant to an evaluation of carcinogenicity. In considering all of the relevant scientific data, the Working Group may assign the agent to a higher or lower category than a strict interpretation of these criteria would indicate. These categories refer only to the strength of the evidence that an exposure is carcinogenic and not to the extent of its carcinogenic activity (potency). Preamble Part B, Section 6 The distinction between hazard and risk is important, and the Monographs identify cancer hazards even when risks are very low at current exposure levels, because new uses or unforeseen exposures could engender risks that are significantly higher. Preamble Part A, Section 2

You may apply an evaluation to a broad grouping of agents or to one specific agent When the agents evaluated are considered by the Working Group to be sufficiently closely related, they may be grouped together for the purpose of a single evaluation of degree of evidence. Preamble Part B, Section 6 In addition, when supporting data indicate that other related agents, for which there is no direct evidence of their capacity to induce cancer in humans or in animals, may also be carcinogenic, a statement describing the rationale for this conclusion is added to the evaluation narrative; an additional evaluation may be made for this broader group of agents... Preamble Part B, Section 6(d) When the available epidemiological studies pertain to a mixture, process, occupation or industry, the Working Group seeks to identify the specific agent considered most likely to be responsible for any excess risk. The evaluation is focused as narrowly as the available data on exposure and other aspects permit. Preamble Part B, Section 6(a)

Guidance can be found in the Preamble The Preamble to the IARC Monographs describes the objective and scope of the programme, the scientific principles and procedures used in developing a Monograph, the types of evidence considered, and the scientific criteria that guide the evaluations. A. GENERAL PRINCIPLES AND PROCEDURES 1. Background 2. Objective and scope 3. Selection of agents for review 4. Data for the Monographs 5. Meeting participants 6. Working procedures B. SCIENTIFIC REVIEW AND EVALUATION 1. Exposure data 2. Studies of cancer in humans 3. Studies of cancer in experimental animals 4. Mechanistic and other relevant data 5. Summary 6. Evaluation and rationale WORLD HEALTH ORGANIZATION INTERNATIONAL AGENCY FOR RESEARCH ON CANCER IARC Monographs on the Evaluation of Carcinogenic Risks to Humans PREAMBLE LYON, FRANCE 2006

The text should present the Working Group s reasoning Concise statements of the principal line(s) of argument that emerge Conclusions of the Working Group on the strength of the evidence for each group of studies Citations to indicate which studies were pivotal to these conclusions Explanation of the reasoning of the Working Group in weighing data and making evaluations Preamble Part B, Section 6(e)

Plenary session humans Sufficient evidence Limited evidence Inadequate evidence Evidence suggesting lack of carcinogenicity experimental animals Sufficient evidence Limited evidence Inadequate evidence Evidence suggesting lack of carcinogenicity Mechanistic and other relevant data Mechanistic data weak, moderate, or strong? Mechanism likely to be operative in humans? Overall evaluation Group 1 Group 2A Group 2B Group 3 Group 4 Carcinogenic to humans Probably carcinogenic to humans Possibly carcinogenic to humans Not classifiable as to its carcinogenicity to humans Probably not carcinogenic to humans